17543CON2(AP)

**PATENT** 

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andrews et al.

Serial No.: 10/829,139

Conf. No.:

Filed: April 20, 2004

For: Kinase Inhibitors for the

Treatment of Disease

Examiner: Not yet assigned

Group Art Unit: Not yet assigned

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Supplemental Information Disclosure Statement-Non Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date of Deposit: Person making Deposit:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Alexandria, VA 22313-1450

Dear Sir:

Applicant herewith submits forms PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 (b). By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentablility of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Each item of information contained in this Supplemental Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

17543CON2(AP) Serial No. 10/829,139

**PATENT** 

Applicant respectfully requests that the Examiner indicate consideration of the references cited by returning PTO Form 1449 with the Examiner's initials and bearing an indication of the date considered.

No fee is thought due in connection with this communication, however, if Applicant is in error in this regard, kindly us our Deposit Account 01-0885 for payment of any fees due herewith.

Respectfully submitted,

Date: 7 1 04

Robert J. Baran Reg. No. 25,806

ALLERGAN, INC. -T2-7H

2525 Dupont Drive Irvine, CA 92612

Tel: 714-246-4669 Fax: 714-246-4249

PATENT AND TRADEMARK OFFICE FORM PTO-1449	Sheet 1 of 1
C LIST OF	REFERENCES CITED BY APPLICANT
ATTY. DOCKET: 17543CON2(AP)	SERIAL NO.: 10/829,139
APPLICANT: Andrews et al	TITLE: KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
FILING DATE: April 20, 2004	GROUP: Not Assigned

#### U.S. PATENT DOCUMENTS

*	EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
		DA	6,451,838 B1	9/17/2002	Moon et al			

#### FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
DB	01/90068	11/29/2001	wo			
DC	03/015608	2/27/2003	wo		l	

### OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

- [	DE		Braud et al. "Potential Inhibitors of Angiogenesis. Part I: 3-(Imidazol-4(5)-ylmethylene)indoline-2-ones", Journal of Enzyme
- 1	101	l :	braud et al., 1 otential infibitors of ringlogenesis. Tart is 5 (infibitive 4.5) fine the first file of the state of the s
ŀ			Inhibition and Medicinal Chemistry", Vol. 18, No. 3, June 2003, 243-252

EXAMINER\_\_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_\_ \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant